Published Research

Medication Risk Mitigation & Clinical Decision Support

  1. Bankes, D, Jin, H, Finnel, S, Michaud, V, Knowlton, CH, Turgeon, J, and Stein, A. Association of a Novel Medication Risk Score with Adverse Drug Events and Other Pertinent Outcomes Among Participants of the Programs of All-Inclusive Care for the Elderly. Pharmacy 2020, 8(2), 87.
  2. Bain KT, Knowlton CH, Turgeon J. Medication Risk Mitigation: Coordinating and Collaborating with Health Care Systems, Universities, and Researchers to Facilitate the Design and Execution of Practice-Based Research. Clin Geriatr Med 2017;33(2):257-281.
  3. Bain KT, Holmes HM, Beers MH, Maio V, Handler SM, Pauker SG. Discontinuing Medications: A Novel Approach for Revising the Prescribing Stage of the Medication-Use Process. J Am Geriatr Soc 2008;56(10):1946-1952.
  4. Turgeon J, Michaud V. Clinical Decisions Support Systems: Great Promises for Better Management of Patients’ Drug Therapy. Expert Opin Drug Metab Toxicol 2016;12(9):993-995.

Competitive Inhibition & Pharmacogenomics

  1. Bain KT, Schwartz EJ, Knowlton OV, Knowlton CH, Turgeon J. Implementation of a Pharmacist-Led Pharmacogenomics Service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE). J Am Pharm Assoc 2018;58(3):281-289.
  2. Schwartz EJ, Turgeon J, Patel J, Patel P, Shah H, Issa AM, Knowlton OV, Knowlton CH, Bain KT. Implementation of a Standardized Medication Therapy Management Plus Approach within Primary Care. J Am Board Fam Med 2017;30(6):701-714.
  3. Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and Risk of Potential Cytochrome P450-Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy. Ann Pharmacother 2013;47(3):324-332.
  4. Zakrzewski-Jakubiak H, Doan J, Lamoureux P, Singh D, Turgeon J, Tannenbaum C. Detection and Prevention of Drug-Drug Interactions in the Hospitalized Elderly: Utility of New Cytochrome P450-Based Software. Am J Geriatr Pharmacother 2011;9(6):461-470.

Drug Burden

  1. Turgeon J, Michaud V, Steffen L. The Dangers of Polypharmacy in Elderly Patients. JAMA Intern Med 2017;177(10):1544.
  2. Bain KT. Anticholinergic Burden: Tracking Adverse Effects. Aging Well. 2011;4(2):8-11.
  3. Bain KT. Adverse Drug Reactions and Current State of Drug Regimen Review in Nursing Facilities: Need for a Change? Consult Pharm 2007;22(7):586-592.
  4. Bain KT, Weschules DJ, Tillotson P. Prevalence and Predictors of Medication-related Problems. Medicare Patient Management 2006;1(1):14-27.

Long QT Syndrome

  1. Turgeon J, Michaud V, Steffen L. The Dangers of Polypharmacy in Elderly Patients. JAMA Intern Med 2017;177(10):1544.
  2. Plante I, Vigneault P, Drolet B, Turgeon J. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci 2012;101(2):868-878.
  3. Caillier B, Pilote S, Castonguay A, et al. QRS Widening and QT Prolongation under Bupropion: a Unique Cardiac Electrophysiological Profile. Fundam Clin Pharmacol 2012;26(5):599-608.
  4. Hreiche R, Morissette P, Turgeon J. Drug-induced long QT syndrome in women: review of current evidence and remaining gaps. Gend Med 2008;5(2):124-135.

Risk Stratification

  1. Cicali B, Michaud V, Knowlton C, Turgeon J. Application of a Novel Medication-Related Risk Stratification Strategy to a Self-Funded Employer’s Population. Benefits Quarterly. Q2 2018.